Silencing ERK Signaling Pathway in TNBC by Silencing BAG3

Authors

  • Junbo Fan Author

DOI:

https://doi.org/10.61173/npywnb04

Keywords:

TNBC, ERK Pathway, BAG3, EGFR, U0126, Proliferation

Abstract

TNBC(Triple negative breast cancer) is cancer with a high mortality rate and recurrence rate. Other studies have shown
that overexpression of EGFR in TNBC is also associated with the overexpression of BAG3 and that silencing of BAG3
will downregulate the expression of EGFR. This study investigates the possible molecular function of BAG3 in treating
TNBC by silencing BAG3, weakening the efficiency of the ERK signaling pathway in vivo and in vitro. The study will
use BT-549 human breast cancer cell lines, with negative control, a wild-type cancer cell, and positive control treated
with YM-1. CRISPR knockout BAG3 will change the expression of BAG3 in the sample, while U0126 treatment
maintains the silencing of the ERK signaling pathway. Using MTT assay and xenograft metastasis, the growth and
migration of cancer cells will be tested; the western blot result will show the molecular process after the inhibition of
BAG3. These results, collectively, can show whether or not a knockout of BAG3 can downregulate EGFR by weakening
the ERK signaling pathway.

Downloads

Published

2023-06-01

Issue

Section

Articles